24 results
DEF 14A
IMCR
Immunocore Holdings plc
12 Apr 24
Definitive proxy
4:20pm
into employment agreements with our executive officers based in the United States and a contract of employment with Ms. St. Leger, our Chief Human Resources Officer … ., Ph.D.
Head of Research and Development
Tina St. Leger
Chief Human Resources Officer
Biographical information for Dr. Jallal is included above
PRE 14A
IMCR
Immunocore Holdings plc
2 Apr 24
Preliminary proxy
4:45pm
into employment agreements with our executive officers based in the United States and a contract of employment with Ms. St. Leger, our Chief Human Resources Officer … ., Ph.D.
Head of Research and Development
Tina St. Leger
Chief Human Resources Officer
Biographical information for Dr. Jallal is included above
10-K
2023 FY
IMCR
Immunocore Holdings plc
28 Feb 24
Annual report
7:33am
, information systems, facilities, human resources or administrative support. Further, we have 139 employees (28%) who hold Ph.D. degrees. None of our … and disease targets require substantial technical, financial and human resources, whether or not they are ultimately successful. For example, we develop
10-K
2023 FY
EX-10.14
IMCR
Immunocore Holdings plc
28 Feb 24
Annual report
7:33am
AND REPORTING STRUCTURE
You are employed in the position of Chief Human Resources Officer and your duties will be designated from time to time … are to be found on THE COMPANY’s intranet.
Study leave may be given by arrangement with your manager and Human Resources when any exams are sat.
Occasionally
6-K
EX-99.2
IMCR
Immunocore Holdings plc
7 Nov 23
Current report (foreign)
7:09am
finance, legal, human resources, commercial expenses, information technology, as well as facility-related costs and foreign currency movements.
Following
6-K
EX-99.2
cm9ag5 a95sughdbfj8
10 Aug 23
Current report (foreign)
8:28am
6-K
EX-99.2
at4hzc2l
10 May 23
Current report (foreign)
7:27am
6-K
EX-99.2
yse8v
9 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:15am
6-K
EX-99.2
1plo4z9a eej
10 Aug 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
8:00am
D
u6fj8eg15zswhk
28 Jul 22
$140M in equity, sold $140M, 8 investors
4:57pm
6-K
EX-99.2
locxebj
11 May 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:08am
6-K
EX-99.2
os6w5w0
10 Nov 21
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:01am
6-K
EX-99.2
k1btvbmngk83c6qis
11 Aug 21
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:00am
6-K
EX-99.2
89i9vy77mcg pzx
12 May 21
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:00am
20-F
cacn rsubq1bbj
25 Mar 21
Annual report (foreign)
7:01am
20-F
EX-4.20
qktdk4lz2vn
25 Mar 21
Annual report (foreign)
7:01am
424B4
875sdjq8
8 Feb 21
Prospectus supplement with pricing info
8:36am
F-1/A
snw0428z8he wfhghi0
3 Feb 21
Registration statement (foreign) (amended)
5:22pm
F-1/A
sy0ywgbbs3pz8 gr4u
1 Feb 21
Registration statement (foreign) (amended)
6:21am